Risks and benefits of celecoxib to prevent colorectal adenomas.
Andersohn
Frank
F
Suissa
Samy
S
Garbe
Edeltraut
E
D000236:Adenoma / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000453:epidemiology / Q000401:mortality; D000068579:Celecoxib; D015179:Colorectal Neoplasms / Q000517:prevention & control; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D006801:Humans; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000453:epidemiology; D009422:Nervous System Diseases / Q000139:chemically induced; D011720:Pyrazoles / Q000009:adverse effects*; D012306:Risk; D020521:Stroke / Q000139:chemically induced* / Q000453:epidemiology; D013449:Sulfonamides / Q000009:adverse effects*
D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib